RFA: Real-World Data Impact Award (RWIA)

A Collaboration Between the American Cancer Society and Flatiron Health, Inc.

All applicants shall be subject to the terms and conditions of a separate confidentiality agreement between Flatiron and the Grantee. Current and former, RWIA grantees are not eligible to apply.

Budget: $75,000 direct cost for a 1-year award period, no indirect costs are allowed

Award Mechanisms: This RFA will use the ACS FHI Real-World Data Impact Award mechanism (RWIA). Applicants selected for invitation based on LOI review will receive complete instructions on this mechanism.

Scope of Research: Novel research utilizing existing Flatiron Health, Inc. (FHI) cancer patient data to explore areas that may lead to improvements in US public health, public policy, and quality of cancer care.

FHI curates information from electronic health records, with 19 disease-specific data sets available for research under the award mechanism. Here are examples of research topics within scope of the award.

Mark Your Calendar

Applications Open in proposalCENTRAL: 
January 2022

Interactive Webinar to Learn More: 
December 14, 2021 from 2 PM ET (Webinar will be recorded and available upon request.)

Microsoft Teams meeting
Join on computer or mobile app. 
Click here to join the meeting
Or call in (audio only) +1 917-727-7985 
Conference ID: 167 018 319#

Signed Non-disclosure Agreement Due: January 7, 2022

LOI Due Date: January 31, 2022 at 11:59 pm ET

Invitation-to-Apply Date:
March 28, 2022

Application Deadline (if invited): 
April 29, 2022

Award Notification: September 2022

Grant Activation: October 2022

Applicants should review the American Cancer Society’s Grant Policies and the instructions about the RWIA.

  • Characterizing healthcare disparities in treatment and outcomes among underserved populations to inform efforts toward achieving health equity
  • Evaluating the impact of national healthcare policy on providers’ practice patterns and on patient outcomes across the cancer continuum
  • Comparing the effectiveness of treatments unlikely to be addressed within cancer clinical trials
  • Assessing the impact of clinical guidelines on cancer care, treatment, and outcomes
  • Developing or validating models to predict cancer risk or to stratify risk(s) to inform stepped care

Note: The list above is not comprehensive. See previously published research utilizing Flatiron Health, Inc. data.

Intent to Apply: Investigators interested in applying for a supplemental award need to first sign a confidentiality agreement with Flatiron Health in proposalCENTRAL (i.e., Pre-LOI) and then submit a letter of intent (LOI). Investigators meeting the eligibility criteria are automatically invited via proposalCENTRAL to submit the pre-LOI. There will be a webinar for potential applicants to learn more about FHI datasets.

Interactive Webinar about the Funding Opportunity

  • Date: Tuesday December 14, 2021 at 2 PM ET
  • Link: Click here to join the meeting
  • To call into the meeting: 1-917-727-7985 || Conference ID: 167 018 319#
  • Interested grantees can hear an overview of this funding opportunity and FHI’s data. There will be ample time to ask questions.
  • The webinar will be recorded and made available upon request.

FHI Nondisclosure Confidentiality Agreement

  • Due: Friday January 7, 2022
  • See “ACS-FHI Real-World Data Impact Award: FHI Nondisclosure Confidentiality Agreement” in proposalCENTRAL.
  • Download, sign, and upload as a PDF the FHI confidentiality agreement in proposalCENTRAL.
  • Once signed, upload it in proposalCENTRAL. Clicking save allows access to general information about available FHI data sets, data elements, and data dictionary.

Letter of Intent (LOI)

  • Due: Monday January 31, 2022
  • LOI Instructions and Templates: See “ACS-FHI Real-World Data Impact Award”
  • LOIs are required and must include in a maximum of 3 pages:
    • Title of proposed research
    • PI and Study Team Information: PI contact information, PI administrative assistant’s contact information, and the names and roles of team members
    • Disease of Interest: Cancer/Cancer Area of Interest
    • Study Overview: Include the disease data sets of interest, brief background about the research plan, specific aims and hypothesis, data elements required, cohort inclusion/exclusion criteria, study design, data analysis plan, and expected significance and impact.
    • NIH Biosketch: Required for PI and Study Team

LOI Review Process: A two-phased process will be used to determine which investigators will be invited to submit supplemental award proposals.

Phase 1: Feasibility Assessment. FHI will review the LOIs, and corresponding data needs to determine if the proposed research question is one that can be feasibly answered using FHI data.

Phase 2: Scientific Review. Upon favorable review by FHI, a scientific LOI Selection Committee will review the LOIs for scientific merit. Invitation-to-apply decisions will be communicated to applicants via proposalCENTRAL by Monday March 28, 2022.

Applicants should review the American Cancer Society’s Grant Policies and the instructions about the RWIA.

Full Applications: For grantees who are invited to apply, full applications are due Friday April 29, 2022.

Application Peer Review: June 2022

Award Notification: September 2022

Funds Available for Awards: Funds will support up to 3 Real-World Data Impact awards. Awarded institutions will contract with ACS using their individual Terms and Conditions. All awardees will be required to comply with the terms and conditions in the FHI nondisclosure confidentiality agreement and the FHI data use agreement, which outlines the terms and conditions required for the Grantee’s use, receipt, and storage of FHI licensed data.

Additional Questions: For questions about this award mechanism please contact Kim Clarke at kimberly.clarke@cancer.org

Goes to proposalCENTRAL